Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

957
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
957
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

764
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
764
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

698
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
698
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

1.1K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.1K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

651
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
651
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

653
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
653

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Liver stiffness at baseline as a marker of hepatocellular carcinoma in cirrhosis: A matched analysis.

World journal of gastrointestinal pathophysiology·2026
Same author

Navigating Treatment Selection in Acute Severe Ulcerative Colitis: A Prospective Mixed Method Analysis of Factors Influencing Patient Decision-Making.

Digestive diseases and sciences·2026
Same author

HLA-DRB1*01:03 in patients with inflammatory bowel disease: a genotype-phenotype association study.

The lancet. Gastroenterology & hepatology·2026
Same author

Evolving prokinetic therapy: New targets and therapeutic opportunities in gastrointestinal motility disorders.

World journal of gastrointestinal pharmacology and therapeutics·2026
Same author

Editorial: Upadacitinib in Perianal Crohn's Disease.

Alimentary pharmacology & therapeutics·2026
Same author

Use of cyclosporine in acute severe ulcerative colitis with low blood cholesterol level: An early experience.

Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology·2026
Same journal

Editorial: Non-Selective Beta-Blockers in Decompensated Cirrhosis-More Friends Than Foes.

Alimentary pharmacology & therapeutics·2026
Same journal

Letter: Reconciling Histological Fibrosis Improvement With Magnetic Resonance Elastography After Sleeve Gastrectomy.

Alimentary pharmacology & therapeutics·2026
Same journal

Letter on: Pre-Emptive Initiation of Continuous Renal Replacement Therapy in Patients With Acute Liver Failure With Cerebral Edema Improves Outcomes: A Randomized Controlled Trial.

Alimentary pharmacology & therapeutics·2026
Same journal

Risk of Myeloproliferative Neoplasms in Patients With Inflammatory Bowel Disease and Impact on Outcomes: A Multi-Centre Matched Analysis.

Alimentary pharmacology & therapeutics·2026
Same journal

Biomarkers in Liver Transplantation for Hepatocellular Carcinoma: Towards Precision Medicine.

Alimentary pharmacology & therapeutics·2026
Same journal

Elobixibat Versus Prucalopride in Functional Constipation: A Prospective Comparative Effectiveness Study.

Alimentary pharmacology & therapeutics·2026
See all related articles

Related Experiment Video

Updated: Apr 7, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

597

Review Article: TL1A Inhibitors in IBD - Mechanistic Rationale and Clinical Evidence.

Manjeet Kumar Goyal1, Harsh Srivastava2, Tanisha Sehgal3

  • 1Department of Internal Medicine, Cleveland Clinic Akron General, Akron, Ohio, USA.

Alimentary Pharmacology & Therapeutics
|April 6, 2026
PubMed
Summary
This summary is machine-generated.

Tumour necrosis factor-like ligand 1A (TL1A) and its receptor DR3 are key in inflammatory bowel diseases (IBD). Inhibiting this axis shows promise for treating IBD by addressing both inflammation and fibrosis.

Keywords:
TL1Aafimkibartcrohn's diseaseduvakituginflammatory bowel diseasestulisokibarttumour necrosis factor‐like ligand 1Aulcerative colitis

More Related Videos

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
10:21

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

7.9K
Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

3.3K

Related Experiment Videos

Last Updated: Apr 7, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

597
Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
10:21

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

7.9K
Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

3.3K

Area of Science:

  • Gastroenterology
  • Immunology
  • Molecular Biology

Background:

  • The TL1A-DR3 signaling pathway is crucial in linking immune responses, epithelial barrier defects, and fibrosis in inflammatory bowel diseases (IBD).
  • Understanding this axis is vital for developing targeted therapies for IBD.

Purpose of the Study:

  • To review the molecular mechanisms of the TL1A-DR3 axis.
  • To explore its role in intestinal inflammation, fibrosis, and extraintestinal manifestations in IBD.
  • To summarize emerging therapies targeting TL1A inhibition for IBD treatment.

Main Methods:

  • A narrative synthesis approach was used.
  • Literature search included preclinical, translational, and clinical studies.
  • Focus was on TL1A/DR3 in Crohn's disease and ulcerative colitis.

Main Results:

  • TL1A overexpression exacerbates ileitis, barrier dysfunction, and fibrosis in disease models.
  • Blocking TL1A effectively reduces both inflammation and tissue remodeling.
  • Early trials of TL1A inhibitors (e.g., tulisokibart, duvakitug) demonstrate clinical and endoscopic remission in moderate-to-severe IBD.

Conclusions:

  • The TL1A-DR3 pathway connects mucosal immunity with stromal damage.
  • TL1A inhibitors represent a new therapeutic class for IBD.
  • Targeting the inflammation-fibrosis continuum offers a novel strategy to improve IBD treatment outcomes.